Do analysts believe Reata Pharmaceuticals (USA Stocks:RETA) will continue to rise?

RETA Stock  USD 87.71  0.19  0.22%   
The next financial report is expected on the 9th of May 2023. The stock is undergoing above-average trading activities. While many traders are getting carried away by overanalyzing pharmaceuticals space, it is reasonable to go over Reata Pharmaceuticals under the current economic conditions. We will cover the possibilities of Reata Pharmaceuticals recovering given the current economic outlook.
Published over three weeks ago
View all stories for Reata Pharmaceuticals | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

Reata Pharmaceuticals holds a performance score of 8 on a scale of zero to a hundred. The company holds a Beta of 1.003, which implies a somewhat significant risk relative to the market. Let's try to break down what Reata's beta means in this case. Reata Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Reata Pharmaceuticals is expected to follow. Although it is essential to pay attention to Reata Pharmaceuticals current trending patterns, it is also good to be reasonable about what you can do with equity existing price patterns. Our philosophy towards forecasting future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Reata Pharmaceuticals expected return of 3.05 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Reata Pharmaceuticals information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis to analyze future returns on Reata Pharmaceuticals.
What is the right price you would pay to acquire a share of Reata Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Reata Pharmaceuticals this year

Annual and quarterly reports issued by Reata Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to Reata stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Reata Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How does Reata utilize its cash?

To perform a cash flow analysis of Reata Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Reata Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Reata Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Reata Pharmaceuticals Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (204.27 Million)

Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals

Legal trades by Reata Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Reata insider trading alert for sale of class a common stock by Michael Wortley, Chief Legal Officer, on 8th of March 2023. This event was filed by Reata Pharmaceuticals Inc with SEC on 2023-03-08. Statement of changes in beneficial ownership - SEC Form 4. Michael Wortley currently serves as vice president chief legal officer of Reata Pharmaceuticals [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Reata a risky opportunity?

Let's check the volatility. Reata is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Reata (USA Stocks:RETA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Reata Pharmaceuticals stock makes you a part-owner of that company.

Reata Pharmaceuticals Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Reata Pharmaceuticals. The Reata consensus assessment is calculated by taking the average estimates from all of the analysts covering Reata Pharmaceuticals

Strong Buy
Strong Buy880.0
Strong Sell00.0

Another 3 percent rise for Reata Pharmaceuticals

Current risk adjusted performance is at 0.11.
As of the 3rd of March, Reata Pharmaceuticals holds the Semi Deviation of 5.45, risk adjusted performance of 0.1149, and Coefficient Of Variation of 872.83. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Reata Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Reata Pharmaceuticals, which can be compared to its competitors. Please check Reata Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Reata Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 90.87 per share. Given that Reata Pharmaceuticals has jensen alpha of 2.95, we recommend you to check out Reata Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Our Final Take On Reata Pharmaceuticals

Whereas few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Reata Pharmaceuticals may offer a potential longer-term growth to investors. To sum up, as of the 3rd of March 2023, our latest 90 days recommendation on the company is Strong Hold. We believe Reata Pharmaceuticals is overvalued with very small probability of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Reata Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to